null

Platform

microRNAs are a class of small non-coding regulatory RNA molecules, which modulate target gene expression and protein production, and whose levels often change in disease. Certain microRNAs are enriched, i.e. present at higher concentration, in different brain regions (e.g. hippocampus, midbrain), cells (e.g. neurons), and cellular compartments (e.g. synapses and neurites). microRNAs can cross the blood-brain barrier and be detected in the bloodstream. Development of neurodegenerative and other neurological diseases is often accompanied by synapse dysfunction and/or loss. Thus, microRNAs enriched in the brain, present in synapses and detectable in plasma can be powerful and patient-friendly biomarkers of brain health.

null

Programs

Early (including presymptomatic), minimally invasive and accurate detection of neurodegenerative diseases, such as Alzheimer’s disease, could facilitate screening and enrollment of participants into clinical trials, and enable disease progression and treatment response monitoring.

CogniMIRTM is a lead product candidate in our pipeline in development for early detection of mild cognitive impairment and Alzheimer’s disease.

Read more

Biomarkers indicative of disease severity and progression are much needed for conditions such as Rett syndrome and autism to enable early detection and therapeutic intervention, and monitoring of response to treatment in pre-clinical and clinical studies.

Read more

Aging is the most significant risk factor for the vast majority of serious human diseases. Effective biomarkers of aging could be critical for development of anti-aging therapeutic regimens to sustain brain health and delay aging.

Read more

Early, preferably presymptomatic, disease detection leads to improved health outcomes. Blood-based Universal Screening Test comprised of organ-enriched microRNA panels could be used to detect presence of pathology in a particular organ or organ system.

Read more

null

Intellectual Property

DiamiR owns worldwide rights to our technology and product candidates in development. The DiamiR team is diligently working on building a solid IP portfolio: several families of issued and pending patents cover the company’s discoveries, innovations, and applications of the technology.

null

Publications